Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms21145145 http://scihub22266oqcxt.onion/10.3390/ijms21145145 32708112!7404132!32708112     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Mol+Sci 2020 ; 21 (14): ä Nephropedia Template TP {{tp|p=32708112|t=2020. COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis |pdf=|usr=}}{{32708112}} gab.com Text COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32708112 #FOAvip Coronavirus 2 (CoV) Severe Acute Respiratory Syndrome (SARS-CoV2) is causing a highly infectious pandemic pneumonia. Coronaviruses are positive sense single-stranded RNA viruses that infect several animal species, causing symptoms that range from those similar to the common cold to severe respiratory syndrome. The Angiotensin Converting Enzyme 2 (ACE2) is the SARS-CoV2 functional receptor. Measures are currently undertaken worldwide to control the infection to avoid disruption of the social and economic equilibrium, especially in countries with poor healthcare resources. In a guarded optimistic view, we hope that the undertaken preventive and treatment measures will at least contribute to contain viral diffusion, attenuate activity, or even eliminate SARS-CoV2. In this review, we discuss emerging perspectives for prevention/treatment of COVID-19 infection. In addition to vaccines under development, passive immunization is an open opportunity since patients develop neutralizing antibodies. A full spectrum of potential drugs for COVID-19 infections could in turn affect virus binding or enzymatic activities involved in viral replication and transcription. Furthermore, clinical trials are currently evaluating the safety and efficacy of anti-inflammatory drugs, such as tocilizumab. Bioinformatics may allow characterization of specific CD8+ and CD4+ T cell responses; thus, CoV2 T cells' frequency can be correlated with the disease severity and outcome. Combinatorial antibody phage display may be empowered to identify the immune repertoire of CoV2-specific neutralizing antibodies. Twit Text FOAVip COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32708112 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32708112 #FOAvip English Wikipedia <ref>{{Cite pmid|32708112}}</ref> COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis #MMPMID32708112 Fierabracci A; Arena A; Rossi P Int J Mol Sci 2020[Jul]; 21 (14): ä PMID32708112show ga Coronavirus 2 (CoV) Severe Acute Respiratory Syndrome (SARS-CoV2) is causing a highly infectious pandemic pneumonia. Coronaviruses are positive sense single-stranded RNA viruses that infect several animal species, causing symptoms that range from those similar to the common cold to severe respiratory syndrome. The Angiotensin Converting Enzyme 2 (ACE2) is the SARS-CoV2 functional receptor. Measures are currently undertaken worldwide to control the infection to avoid disruption of the social and economic equilibrium, especially in countries with poor healthcare resources. In a guarded optimistic view, we hope that the undertaken preventive and treatment measures will at least contribute to contain viral diffusion, attenuate activity, or even eliminate SARS-CoV2. In this review, we discuss emerging perspectives for prevention/treatment of COVID-19 infection. In addition to vaccines under development, passive immunization is an open opportunity since patients develop neutralizing antibodies. A full spectrum of potential drugs for COVID-19 infections could in turn affect virus binding or enzymatic activities involved in viral replication and transcription. Furthermore, clinical trials are currently evaluating the safety and efficacy of anti-inflammatory drugs, such as tocilizumab. Bioinformatics may allow characterization of specific CD8+ and CD4+ T cell responses; thus, CoV2 T cells' frequency can be correlated with the disease severity and outcome. Combinatorial antibody phage display may be empowered to identify the immune repertoire of CoV2-specific neutralizing antibodies. |*Coronavirus Infections/diagnosis/drug therapy/prevention & control[MESH] |*Pandemics/prevention & control[MESH] |*Pneumonia, Viral/diagnosis/drug therapy/prevention & control[MESH] |A549 Cells[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |Anti-Inflammatory Agents/therapeutic use[MESH] |Antibodies, Neutralizing/immunology/*therapeutic use[MESH] |Antibodies, Viral/immunology/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/drug effects/immunology[MESH] |CD4-Positive T-Lymphocytes/immunology[MESH] |CD8-Positive T-Lymphocytes/immunology[MESH] |COVID-19[MESH] |Cell Line[MESH] |Chlorocebus aethiops[MESH] |Humans[MESH] |Immunization, Passive/*methods[MESH] |Lymphocyte Count[MESH] |Peptidyl-Dipeptidase A/metabolism[MESH] |SARS-CoV-2[MESH] |Spike Glycoprotein, Coronavirus/metabolism[MESH]COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis (epmc).pdf DeepDyve Pubget Overpricing